Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Advances in systemic therapies for triple negative breast cancer
RA Leon-Ferre, MP Goetz - Bmj, 2023 - bmj.com
Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the
highest rates of recurrence and mortality. The lack of expression of targetable proteins such …
highest rates of recurrence and mortality. The lack of expression of targetable proteins such …
Clinical cancer immunotherapy: Current progress and prospects
C Liu, M Yang, D Zhang, M Chen, D Zhu - Frontiers in immunology, 2022 - frontiersin.org
Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and
robust therapeutic potential in clinical practice. It can significantly improve progression-free …
robust therapeutic potential in clinical practice. It can significantly improve progression-free …
Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …
L Connelly‐Smith, CR Alquist, NA Aqui… - Journal of clinical …, 2023 - Wiley Online Library
Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non–small-cell lung cancer in CheckMate 227
JR Brahmer, JS Lee, TE Ciuleanu… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus
ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic …
ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic …
Immune-related adverse events of immune checkpoint inhibitors: a review
Q Yin, L Wu, L Han, X Zheng, R Tong, L Li… - Frontiers in …, 2023 - frontiersin.org
Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has
entered a new era, and the response rate and survival rate of many cancers have also been …
entered a new era, and the response rate and survival rate of many cancers have also been …
Myocarditis
C Basso - New England Journal of Medicine, 2022 - Mass Medical Soc
Myocarditis | New England Journal of Medicine Skip to main content The New England Journal
of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology Clinical Medicine …
of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology Clinical Medicine …
Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline
MA Shah, EB Kennedy, AE Alarcon-Rozas… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE To develop recommendations involving targeted therapies for patients with
advanced gastroesophageal cancer. METHODS The American Society of Clinical Oncology …
advanced gastroesophageal cancer. METHODS The American Society of Clinical Oncology …
Abatacept/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis
JE Salem, M Bretagne, B Abbar… - Cancer …, 2023 - aacrjournals.org
Abstract Immune-checkpoint-inhibitor (ICI)–associated myotoxicity involves the heart
(myocarditis) and skeletal muscles (myositis), which frequently occur concurrently and are …
(myocarditis) and skeletal muscles (myositis), which frequently occur concurrently and are …
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
AJ Bullock, BL Schlechter, MG Fakih… - Nature medicine, 2024 - nature.com
Microsatellite stable metastatic colorectal cancer (MSS mCRC; mismatch repair proficient)
has previously responded poorly to immune checkpoint blockade. Botensilimab (BOT) is an …
has previously responded poorly to immune checkpoint blockade. Botensilimab (BOT) is an …
Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data
Abstract Purpose Immune checkpoint inhibitors (ICIs) are related to various immune-related
adverse events (irAEs). However, the knowledge is limited with rare irAEs like hearing loss …
adverse events (irAEs). However, the knowledge is limited with rare irAEs like hearing loss …